Cedar Grove Capital Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Eye care company Alcon Inc., which has a major presence in North Texas, plans to buy Lensar Inc. in a deal valued up to $430 million. Orlando-based Lensar (Nasdaq: LNSR) is a laser cataract ...

Alcon ALC and LENSAR, Inc. LNSR, a global medical technology company focused on advanced laser solutions for the treatment of cataracts, recently entered into a definitive merger agreement.

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on advanced laser ...

The LENSAR Inc (LNSR) reports a 38% revenue increase in Q4 2024, driven by strong ALLY system placements and expanding market share. ORLANDO, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- LENSAR ...

Alcon will buy Lensar’s outstanding shares for $14 per share. The deal is expected to close in the second half of 2025. Perspective from John A. Hovanesian, MD, FACS Alcon will expand its ...

Alcon is set to acquire LENSAR Inc. in a $356 million deal. This acquisition includes LENSAR's advanced cataract laser technologies, boosting Alcon's offerings in femtosecond laser-assisted ...

In its first quarter 2025 investor letter, Cedar Grove Capital Management emphasized stocks such as LENSAR, Inc. (NASDAQ:LNSR). LENSAR, Inc. (NASDAQ:LNSR) is a commercial-stage medical device company.

The acquisition includes ALLY Robotic Cataract Laser Treatment System™, LENSAR’s proprietary Streamline® software technology and LENSAR legacy laser system, building Alcon’s femtosecond ...